Rezolute, Inc. (NASDAQ:RZLT) Stock Has Consensus Price Target of $11.22

Shares of Rezolute, Inc. (NASDAQ:RZLT) have received a consensus rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $11.22.

A number of brokerages have weighed in on RZLT. Zacks Research upgraded shares of Rezolute from a “strong sell” rating to a “hold” rating in a research report on Friday, August 14th. Lake Street Capital boosted their price target on shares of Rezolute from $9.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. Craig Hallum upgraded shares of Rezolute from a “hold” rating to a “buy” rating and upped their price target for the company from $4.00 to $7.00 in a research note on Tuesday, September 29th. Citizens Jmp upped their price target on shares of Rezolute from $11.00 to $15.00 and gave the company a “market outperform” rating in a research note on Tuesday, October 6th. Finally, Guggenheim raised their price objective on shares of Rezolute from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, June 15th.

Rezolute Stock Performance

Shares of NASDAQ RZLT opened at $4.87 on Thursday. The stock has a fifty day simple moving average of $4.46 and a two-hundred day simple moving average of $4.15. Rezolute has a 1-year low of $1.07 and a 1-year high of $11.46. The firm has a market cap of $471.08 million, a price-to-earnings ratio of -6.41 and a beta of 0.53.

Rezolute (NASDAQ:RZLT) last issued its earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). Analysts forecast that Rezolute will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Rezolute

Institutional investors have recently made changes to their positions in the stock. Auxano Advisors LLC purchased a new position in shares of Rezolute in the second quarter valued at $52,000. Sequoia Financial Advisors LLC bought a new stake in shares of Rezolute during the 2nd quarter valued at $75,000. WINTON GROUP Ltd purchased a new stake in Rezolute during the 2nd quarter worth about $88,000. Integrated Wealth Concepts LLC purchased a new stake in Rezolute during the 2nd quarter worth about $143,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Rezolute in the 1st quarter worth about $90,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar.